Meet Biori at ASGCT 2026: HCD/HCP Testing, Universal Nuclease, and Custom Kit Development for Cell & Gene Therapy

Biori is pleased to attend ASGCT 2026, one of the key annual gatherings for professionals advancing cell and gene therapy. We look forward to connecting with researchers, process development teams, analytical scientists, CDMOs, and biopharma partners working across viral vectors, mRNA, gene editing, and next-generation therapeutic platforms.

For this event, Biori will focus on three solution areas that are highly relevant to cell and gene therapy development and manufacturing: HCD/HCP testing, universal nuclease, and customized kit development services.

Event Information: ASGCT 2026

• Event: ASGCT 2026 Annual Meeting
• Dates: May 11–15, 2026
• Venue: Thomas M. Menino Convention & Exhibition Center, Boston, Massachusetts, USA
• Biori Booth: Booth No. 1511
• Organizer: American Society of Gene & Cell Therapy

ASGCT brings together the global cell and gene therapy community to share scientific progress, manufacturing strategies, analytical methods, and translational development experience.

ASGCT 2026 CGT QC Solutions: What Biori Will Highlight

Cell and gene therapy products require strict control of process-related impurities, robust analytical methods, and flexible reagent development. At ASGCT 2026, Biori welcomes discussions around practical QC challenges and customized reagent solutions for CGT workflows.

1. HCD/HCP Testing for Biopharma and CGT Quality Control

Residual Host Cell DNA (HCD) and Host Cell Protein (HCP) are critical quality attributes in biologics, viral vector, vaccine, and cell and gene therapy manufacturing. Reliable detection supports process characterization, impurity clearance evaluation, and release testing strategies.

Biori supports customers with HCD/HCP-related solutions for applications such as:

• Residual host cell DNA detection
• Host cell protein detection and monitoring
• Viral vector and biologics process QC
• Vaccine, antibody, and CGT manufacturing quality control
• Assay development support for customer-specific workflows

Whether your team is optimizing upstream production, downstream purification, or analytical release testing, Biori can discuss how HCD/HCP solutions may fit your process control needs.

2. Universal Nuclease for Residual DNA Reduction and Sample Processing

Efficient nucleic acid digestion is important in many biomanufacturing and molecular biology workflows. Biori’s universal nuclease is designed to support applications where broad nucleic acid degradation is required, including sample preparation, process impurity control, and workflow optimization.

Potential discussion areas include:

• Residual DNA reduction in bioprocessing workflows
• Nucleic acid digestion during sample preparation
• Compatibility considerations for different process conditions
• Customized enzyme supply and formulation requirements
• Integration with analytical and QC workflows

For CGT and biopharma teams, nuclease selection can influence process efficiency, impurity control, and downstream analytical consistency. Biori is ready to discuss application-specific requirements and customization options.

3. Customized Kit Development Services

Different cell and gene therapy workflows often require different assay formats, sensitivity requirements, sample matrices, and regulatory documentation needs. Biori provides customized kit development services to help customers build practical reagent and assay solutions aligned with their workflow.

Customization can include:

• Assay and reagent format development
• Kit component optimization
• Buffer and formulation adjustment
• Lyophilized or glycerol-free reagent options
• OEM/private-label support
• Scale-up and batch consistency support

Biori can work with partners from early development to larger-scale supply, helping translate technical requirements into usable kit formats for research, process development, or manufacturing support.

Why HCD/HCP and Nuclease Solutions Matter for CGT Manufacturing

Cell and gene therapy manufacturing involves complex biological systems and sensitive product attributes. As therapies move from research to clinical and commercial stages, teams need reliable tools for impurity monitoring, nucleic acid control, and standardized QC workflows.

Key priorities often include:

• Demonstrating process-related impurity clearance
• Supporting robust analytical method development
• Improving consistency across batches and sites
• Reducing workflow complexity with integrated reagent solutions
• Working with suppliers who understand customization and quality expectations

Biori’s HCD/HCP product line, universal nuclease, and custom kit development services are built to support these practical needs in biopharma and CGT environments.

Who Should Connect with Biori at ASGCT 2026?

We welcome discussions with:

• Cell and gene therapy developers
• Viral vector process development teams
• Biopharma QC and analytical development scientists
• CDMOs and manufacturing service providers
• Vaccine and biologics manufacturers
• Diagnostic and life science reagent distributors
• OEM partners seeking custom kit or reagent development

If your team is working on CGT manufacturing, analytical QC, residual DNA/HCP monitoring, nuclease workflows, or customized assay kits, ASGCT 2026 is a valuable opportunity to connect with Biori.

Beyond CGT QC: Biori’s Broader Reagent Capabilities

In addition to HCD/HCP testing, universal nuclease, and custom kit development, Biori also supports customers with enzyme and reagent solutions across molecular diagnostics and life science workflows, including PCR/qPCR, NGS-related enzymes, OEM reagents, and GMP-grade IVT raw materials for mRNA manufacturing.

For mRNA and IVT-related customers, Biori provides a complete portfolio of GMP-grade IVT raw materials for mRNA manufacturing, including key enzymes and workflow reagents, with OEM and customization support.

• Explore Biori HCD/HCP product selection for biopharma QC
• Learn about Biori custom HCD/HCP assay and kit development services
• View Biori GMP-grade nuclease enzyme solutions
• View Biori GMP-grade IVT raw material solutions

FAQ

What will Biori focus on at ASGCT 2026?

Biori will focus on HCD/HCP testing solutions, universal nuclease, and customized kit development services for cell and gene therapy, biopharma QC, and related manufacturing workflows.

Why are HCD and HCP important in cell and gene therapy manufacturing?

HCD and HCP are process-related impurities that need to be monitored and controlled during biologics and CGT manufacturing. Reliable detection supports process development, impurity clearance evaluation, and quality control strategies.

What is universal nuclease used for?

Universal nuclease can be used for broad nucleic acid digestion in workflows such as residual DNA reduction, sample preparation, and process optimization. Application conditions should be evaluated based on each workflow’s requirements.

Can Biori develop customized kits for specific workflows?

Yes. Biori supports customized kit development, including reagent format design, component optimization, formulation adjustment, lyophilized or glycerol-free options, OEM/private-label support, and scalable supply.

Connect with Biori at ASGCT 2026

If you are attending ASGCT 2026, we welcome the opportunity to discuss your CGT QC challenges, HCD/HCP testing needs, universal nuclease applications, and customized kit development projects.

Contact Biori to schedule a meeting and explore how our reagent and assay development capabilities can support your next stage of cell and gene therapy development.

External reference: ASGCT Annual Meeting official website